Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness

Hydroxyurea (HU), the first of two drugs approved by the US Food and Drug Administration for treating patients with sickle cell disease (SCD), produces anti-sickling effect by re-activating fetal γ-globin gene to enhance production of fetal hemoglobin. However, approximately 30% of the patients do n...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xingguo, Hu, Tianxiang, Ho, Meng Hsuan, Wang, Yongchao, Yu, Miao, Patel, Niren, Pi, Wenhu, Choi, Jeong-Hyeon, Xu, Hongyan, Ganapathy, Vadivel, Kutlar, Ferdane, Kutlar, Abdullah, Tuan, Dorothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709098/
https://www.ncbi.nlm.nih.gov/pubmed/28971909
http://dx.doi.org/10.3324/haematol.2017.175646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709098/
https://www.ncbi.nlm.nih.gov/pubmed/28971909
http://dx.doi.org/10.3324/haematol.2017.175646

Ejemplares similares